Drug resistance

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Retrieved on: 
木曜日, 4月 25, 2024
PFS, Efficacy, Safety, DCR, Risk, Nivolumab, Randomness, SOC, Drug resistance, Death, CM24, Tumor microenvironment, OS, PD-1, PDAC, ASCO, Cancer, Patient, Society, CA19-9, Interim, BMS, Neoplasm, Bristol Myers Squibb, Annual general meeting, Pharmacodynamics, Escape Room, Pharmaceutical industry

REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC), have been selected as late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place on May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • The primary endpoint of the study is overall survival (OS), with progression free survival (PFS) and objective response rate (ORR) as secondary endpoints.
  • The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for hypothesis testing.
  • Approximately 60 patients have been enrolled in the randomized study in 18 centers in the U.S., Spain and Israel.
  • “We are honored to be selected by the ASCO committee with our late breaking abstract poster presentation and are looking forward to presenting our interim results from our randomized Phase 2 CM24 study at the ASCO 2024 annual meeting.” stated Gil Efron, Chief Executive Officer of Purple Biotech.

Microbix Collaborator Introduces New Lab Accreditation Program

Retrieved on: 
木曜日, 4月 25, 2024
RUO, Mycoplasma genitalium, EQA, Pelvic inflammatory disease, Infection, OTCQX, Woman, Infertility, Poster, Bacteria, MDX, AMR, ECCMID, TSX, STI, Accreditation, Vertically transmitted infection, Temperature, Drug resistance, Chronic pain, Non-gonococcal urethritis, Ectopic pregnancy, IVD

The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.

Key Points: 
  • The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.
  • The pilot EQA program confirmed the performance of these QAPs across all clinical labs, instrument platforms, and assays.
  • These Mgen QAPs are now available from Microbix as part of its PROCEEDx®FLOQ® (RUO) or REDx™FLOQ® (IVD) catalogue of products.
  • Purchase enquiries for these or other Microbix QAPs can be e-mailed to [email protected] .

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality

Retrieved on: 
木曜日, 5月 2, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, GV, Harvard University, Cancer, Genetics, Cell, Broad Institute, Survival, GV (company), Drug resistance, Growth, Overload, Oncogene, Patient, Neoplasm, NIBR, Investment, MIT, Pharmaceutical industry

Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.

Key Points: 
  • Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.
  • “Our activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
  • Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
  • Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways.

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Retrieved on: 
水曜日, 4月 10, 2024
IC50, AP3, Drug resistance, Proteomics, PDX, CDX, Cell cycle, PKMYT1, Patient, Medicine, WEE1, Neoplasm, ACRV, AACR, Drug development, Biomarker, Drug discovery, Therapy, Ovarian cancer, Pharmaceutical industry

WATERTOWN, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced data from two posters that the company presented at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • “Uniquely enabled by AP3, we designed a selective and potent dual inhibitor of both WEE1 and PKMYT1, ACR-2316, designed for potent single agent activity.
  • We presented preclinical data showing its superior activity versus benchmark WEE1 and PKMYT1 single-agent inhibitors in multiple cancer models and look forward to advancing this compound into the clinic.
  • The complete responses observed with ACR-2316 in human tumor xenograft mouse models were associated with strong WEE1 and balanced PKMYT1 inhibition activity in tumors.
  • This corresponded with the subsequent upregulation of ACR-368 OncoSignature biomarkers, indicating that the OncoSignature assay can predict which ULDG sensitized tumors would be responsive to treatment with ACR-368.

Malaria No More Commends the U.S. President's Malaria Initiative on Progress in the Face of Increasing Challenges

Retrieved on: 
木曜日, 4月 25, 2024
Congress, Climate change, Administration, Malaria, Risk, Annual report, Drug resistance, PMI, Vaccine, Mosquito, Face, Anopheles, Death, Government, Pharmaceutical industry

"Enormous progress is being made in the face of daunting challenges," said David Walton, U.S.

Key Points: 
  • "Enormous progress is being made in the face of daunting challenges," said David Walton, U.S.
  • "This World Malaria Day, we applaud PMI for continued progress and innovation in the face of increasing challenges.
  • Now is the moment to close the global malaria funding gap for scaling new tools, including game-changing malaria vaccines, to end malaria in our lifetime."
  • For more on the U.S. President's Malaria Initiative and PMI's 18th Annual Report, visit pmi.gov
    For more information or interview requests, please contact Mindy Mizell at [email protected]

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Retrieved on: 
木曜日, 4月 25, 2024
Cancer, NOAEL, Triple-negative breast cancer, Esophageal cancer, IC50, Cell death, Uterine cancer, Drug resistance, Docetaxel, IND, DNA, Patient, Metastasis, Genome, Clinical trial, No-observed-adverse-effect level, Ovarian cancer, Vaccine

SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations.

Key Points: 
  • SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations.
  • Mutations in the p53 gene occur in almost all cancer types and cause intractable cancers such cases found in ovarian cancer, uterine cancer, esophageal cancer, etc.
  • Niclosamide can induce cancer cell death by regulating cancer cell metabolic pathways and can resolve drug resistance and cancer cell metastasis  while minimizing side effects.
  • Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Vast Therapeutics Selected to Present at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit

Retrieved on: 
水曜日, 4月 17, 2024
Drug resistance, Inflammation, Pseudomonas aeruginosa, Nephrotoxicity, Therapy, Quality of life, Patient, Conditional sentence, ALX1, Pharmaceutical industry

MORRISVILLE, N.C., April 17, 2024 /PRNewswire/ -- Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases, today announced an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024.

Key Points: 
  • MORRISVILLE, N.C., April 17, 2024 /PRNewswire/ -- Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases, today announced an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024.
  • Dr. Nathan Stasko, Chief Executive Officer of Vast, will deliver an oral presentation on how its lead candidate, ALX1, is positioned to reshape the treatment landscape for several patient populations chronically infected with Pseudomonas aeruginosa.
  • Session Date and Time: Saturday, May 18 at 10:15 a.m. PT
    "ALX1 has dual antimicrobial and anti-inflammatory activity without the concerns of drug resistance and renal toxicity associated with traditional antibiotics," stated Nathan Stasko, Chief Executive Officer of Vast Therapeutics.
  • "A non-intermittent therapy with no 'on-off' periods is desperately needed to sustainably improve the quality of life and decrease the number of hospitalizations experienced by these patients."

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
月曜日, 4月 8, 2024
NSCLC, Colorectal cancer, CYPA, RAS, Patient, Research, PDAC, Lung cancer, Protein, Trial of the century, GTP, Cancer, CRC, Pharmacology, Ras GTPase, Drug resistance, Pharmaceutical industry

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants.
  • The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC).

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

Retrieved on: 
月曜日, 4月 8, 2024
Sarah Cannon Research Institute, B-cell leukemia, AML, B-ALL, Patient, Webcast, Neoplasm, Acute myeloid leukemia, Cancer, Syndrome, Spacecraft, Camptothecin, AACR, DLT, PALO, Antibody, Drug development, Safety, Infrared spectroscopy correlation table, MDS, Therapy, ADC, Drug resistance, Pharmaceutical industry

PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • We are still in dose escalation and are starting to see tumor reduction after only two doses.
  • The study's main objective is to determine a safe dose and schedule for VIP236 for further clinical development.
  • As the study progresses through the dose escalation, Vincerx will present additional Phase 1 data for VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
日曜日, 4月 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.